Daré Bioscience Future Growth
Future criteria checks 5/6
Daré Bioscience is forecast to grow earnings and revenue by 71.8% and 63.1% per annum respectively while EPS is expected to grow by 71.7% per annum.
Key information
71.8%
Earnings growth rate
71.7%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | 63.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Apr 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Oct 17Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Oct 10Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Aug 29Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Jun 30Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Apr 02Diving Back Into Daré Bioscience Again
Jan 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Nov 26Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study
Apr 26Diving Into Daré Bioscience
Jan 31Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
Dec 22
Dare Bioscience EPS misses by $0.06
Nov 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 63 | 13 | N/A | N/A | 2 |
| 12/31/2025 | 33 | -7 | N/A | N/A | 2 |
| 12/31/2024 | 5 | -30 | N/A | N/A | 2 |
| 12/31/2023 | 3 | -30 | -39 | -39 | N/A |
| 9/30/2023 | 1 | -41 | -37 | -37 | N/A |
| 6/30/2023 | N/A | -40 | -20 | -20 | N/A |
| 3/31/2023 | 10 | -31 | -22 | -22 | N/A |
| 12/31/2022 | 10 | -31 | -18 | -18 | N/A |
| 9/30/2022 | 10 | -25 | -22 | -22 | N/A |
| 6/30/2022 | 10 | -30 | -29 | -29 | N/A |
| 3/31/2022 | N/A | -40 | -33 | -33 | N/A |
| 12/31/2021 | N/A | -39 | -29 | -29 | N/A |
| 9/30/2021 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2021 | N/A | -33 | -35 | -35 | N/A |
| 3/31/2021 | N/A | -30 | -27 | -27 | N/A |
| 12/31/2020 | N/A | -27 | -25 | -25 | N/A |
| 9/30/2020 | N/A | -23 | -20 | -20 | N/A |
| 6/30/2020 | N/A | -19 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -16 | -17 | -17 | N/A |
| 12/31/2019 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2019 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2019 | N/A | -13 | -12 | -12 | N/A |
| 3/31/2019 | N/A | -12 | -12 | -11 | N/A |
| 12/31/2018 | N/A | -17 | -11 | -10 | N/A |
| 9/30/2018 | N/A | -23 | -9 | -9 | N/A |
| 6/30/2018 | N/A | -22 | -8 | -7 | N/A |
| 3/31/2018 | N/A | -19 | -5 | -5 | N/A |
| 12/31/2017 | N/A | -12 | -3 | -3 | N/A |
| 9/30/2017 | N/A | -3 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | 0 | N/A |
| 3/31/2017 | N/A | -1 | N/A | 0 | N/A |
| 12/31/2016 | N/A | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DARE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: DARE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DARE is expected to become profitable in the next 3 years.
Revenue vs Market: DARE's revenue (63.1% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: DARE's revenue (63.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DARE's Return on Equity is forecast to be high in 3 years time